Literature DB >> 25745337

Tuberculous meningitis on directly observed thrice a week regime.

Sora Yasri1, Viroj Wiwanitkit2.   

Abstract

Entities:  

Year:  2015        PMID: 25745337      PMCID: PMC4350206          DOI: 10.4103/0972-2327.144316

Source DB:  PubMed          Journal:  Ann Indian Acad Neurol        ISSN: 0972-2327            Impact factor:   1.383


× No keyword cloud information.
Sir, The recent on “tuberculous meningitis on directly observed thrice a week regime” is interesting.[1] Iype et al., noted that “RNTCP regimen was associated with good compliance, comparable mortality and morbidity.[1]” In fact, Iype et al., has ever reported a highly similar observation in Indian Journal of Tuberculosis and concluded that the new regime is not different from classical regime.[2] In fact, although the intermittent short course regime might seem convenient, the efficacy of this regime is still inconclusive. According to the meta-analysis, it is concluded that “Trials conducted to date are insufficient to support or refute the use of intermittent twice- or thrice-weekly, short-course treatment regimens over daily short-course treatment.[3]” In addition, the efficacy of the regime in cases with concomitant illness especially for HIV infection should be further systematically studied.
  3 in total

1.  In-hospital mortality of intermittent vs daily antitubercular regimen in patients with meningeal tuberculosis--a retrospective study.

Authors:  Thomas Iype; Litta Elizabeth George; Ajith Cherian; Aswini Kumar; B K Ajitha; Sinchu Chandy; K Vijaya Kumar
Journal:  Indian J Tuberc       Date:  2012-01

Review 2.  Intermittent versus daily therapy for treating tuberculosis in children.

Authors:  Anuradha Bose; Soumik Kalita; Winsley Rose; Prathap Tharyan
Journal:  Cochrane Database Syst Rev       Date:  2014-01-28

3.  Major outcomes of patients with tuberculous meningitis on directly observed thrice a week regime.

Authors:  Thomas Iype; Ayyappan Kunjukrishna Pillai; Ajith Cherian; Zinia T Nujum; Chithra Pushpa; Dalus Dae; Vijayakumar Krishnapillai
Journal:  Ann Indian Acad Neurol       Date:  2014-07       Impact factor: 1.383

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.